Xpert Perspectives from DDW 2014: Reporting on Fecal Incontinence

Target Audience

This enduring activity has been designed to meet the educational needs of gastroenterologists, colorectal surgeons, urogynecologists, physician assistants, and nurse practitioners involved in the care of patients with fecal incontinence.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Describe the prevalence and impact of fecal incontinence

Discuss recent data on new modalities for assessing the pathophysiology underlying fecal incontinence

Identify the most important symptoms of fecal incontinence from a patient perspective

Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Gi Health Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 0.5 contact hours may be earned for successful completion of this enduring material. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.5 contact hours.

Release Date: July 18, 2014
Expiration Date: July 18, 2015  
*This program has expired. CME credit is no longer available.

Disclosure

All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education (ACHS), consults for Pfizer, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and The Gi Health Foundation has no relationships to disclose.

Learner Assurance Statement

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Faculty Disclosure

William Chey, MD, has received grants and research support from Ironwood Pharmaceuticals, Inc., Prometheus Laboratories Inc. and Nestlé Health Science. Dr. Chey is a consultant for AstraZeneca, Asubio, Ferring Pharmaceuticals Inc., Forest Laboratories, Ironwood Pharmaceuticals, Inc., Nestlé Health Science, Perrigo Company, Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc., Sucampo, Sandhill and Takeda Pharmaceuticals.

Mark Pimentel, MD, is a consultant for Salix Pharmaceuticals Inc., Synthetic Biologics and Commonwealth Labs. Dr. Pimentel is an advisory board member for Salix Pharmaceuticals Inc. and Synthetic Biologic. Dr. Pimentel has received honorarium from Salix Pharmaceuticals Inc. and Commonwealth Labs. Dr. Pimentel is a stockholder of Synthetic Biologics. Dr. Pimentel has received grants and research support from Salix Pharmaceuticals, Inc. Dr. Pimentel has editorial board involvement with Gastroenterology & Hepatology and The Journal of Gastroenterology and Hepatology. Dr. Pimentel also disclosures Cedars-Sinai has licensing agreements with Salix Pharmaceuticals Inc., Synthetic Biologics, Commonwealth Labs and Micropharma.